How Much Weight Can You Lose on Tirzepatide? Dose-by-Dose Results
Released: Last reviewed:
Tirzepatide produces some of the largest average weight loss of any approved obesity drug — but how much depends on dose. Here is the trial data, dose by dose.
By Dr. Parmis, Lead Medical Researcher · Medically reviewed by Adam Kennah, M.D. · Last reviewed July 9, 2026 · Sources cited at the end.
Direct answer
In the pivotal SURMOUNT-1 trial, adults with obesity lost on average 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg of body weight over 72 weeks, compared with about 3.1% on placebo. At the top dose that averaged roughly 48 pounds. Results rise with dose on average, but the right dose is the one you tolerate under clinician guidance — not automatically the highest.
Weight loss by dose (SURMOUNT-1, 72 weeks)
| Dose | Avg weight loss | Approx. pounds* |
|---|---|---|
| Placebo | 3.1% | ~7 lb |
| 5 mg | 15.0% | ~34 lb |
| 10 mg | 19.5% | ~41 lb |
| 15 mg | 20.9% | ~48 lb |
*Approximate, based on average trial body weight. Individual results vary. Source: SURMOUNT-1 / Zepbound labeling.
What drives your individual result
Trial averages hide wide variation. Real-world outcomes depend on dose reached and tolerated, consistency, diet and activity, sex (men lost slightly less than women in head-to-head data), starting weight, and whether you stay on treatment. Weight tends to return if the medication is stopped, so obesity medicine is generally viewed as long-term.
How tirzepatide compares
Tirzepatide’s averages are among the highest for approved obesity drugs. In the head-to-head SURMOUNT-5 trial it produced 20.2% versus 13.7% for semaglutide. For that comparison and the newer oral pill, see our three-way comparison and SURMOUNT-5 report.
Setting realistic expectations
Think in ranges, not guarantees. Many people reach double-digit percentage loss; some exceed 20%, others less. Pair medication with sustainable habits and clinician follow-up. For dosing mechanics and titration, see our dosing guide and week-by-week timeline.
Why results vary so much between people
Two people on the same dose can land far apart. Genetics, starting weight, sex, sleep, medications, and how consistently someone takes the drug and supports it with nutrition and activity all shape the outcome. Trial averages describe a population reaching and holding the maximum tolerated dose for 72 weeks under close supervision — conditions that are hard to replicate perfectly in daily life. Treat the numbers as a realistic center of gravity, not a promise.
Maintenance: keeping the weight off
Weight loss is only half the story. Studies consistently show that stopping a GLP-1 tends to be followed by regain, because the underlying biology of appetite and metabolism reasserts itself. That is why obesity is increasingly treated as a chronic condition requiring long-term management rather than a short course. If cost or access threatens continuity, that is worth planning for with a clinician before starting, since an interrupted course can undo hard-won progress.
Frequently asked questions
How much weight can you lose on tirzepatide? In the SURMOUNT-1 trial, adults lost about 15% of body weight at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks, versus about 3% on placebo.
Does a higher dose mean more weight loss? On average, yes — results rose with dose in trials. But the highest dose is not right for everyone; tolerability and clinician guidance matter more than chasing the top dose.
How long does it take to see results? Meaningful weight loss typically begins within the first weeks and continues for roughly 72 weeks before tending to plateau, based on the SURMOUNT program.
Is compounded tirzepatide as effective? The trial data come from FDA-approved tirzepatide. Compounded versions are not FDA-approved and can vary in concentration, so results are not guaranteed to match.
July 9, 2026: Published; dose-response figures verified against SURMOUNT-1 reporting.
Reviewed by Adam Kennah, M.D.
Sources
- Jastreboff et al., SURMOUNT-1, New England Journal of Medicine (2022) — via Zepbound approval summary
- Weill Cornell Medicine — head-to-head weight-loss trial coverage
- TrimRx — SURMOUNT-1 trial figures summary
Important: Compounded tirzepatide is not FDA-approved and is not the same medicine as Mounjaro or Zepbound, the only FDA-approved tirzepatide products (Eli Lilly and Company). This page is educational and is not medical or legal advice. Weight-loss medications require evaluation and, when appropriate, a prescription from a licensed clinician. Individual results and side effects vary. Confirm current FDA status, pricing, and clinical guidance directly before acting.